Description
GLP3 / Reta
-
Supplied as a lyophilized powder vial, manufactured to the highest chemical standards. Every batch is strictly synthesized as a reference standard for laboratory evaluation, in-vitro testing, and scientific development purposes.
-
Each size variation is accompanied by an independent third-party Certificate of Analysis (COA) verifying a purity level of 99% or higher, ID, net vial content, endotoxins, and vial conformity.
- https://aminoshoppe.com/lab-tests/
-
Laboratory Research Notice: This product is intended strictly for laboratory research and development use only.
| Clinical data | |
|---|---|
| Other names | LY-3437943 |
| Identifiers | |
| CAS Number | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
|
|
|
GLP3 / R is a peptide with the following amino acid sequence:YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³where letters with superscripted numbers refer to the following chemical modifications:
-
A¹ –2-aminoisobuttyric acid
-
L² – leucine modified with an α-methyl substituent (MeL, 2-methylleucine).
-
S³ – L-serinamide (L-serine with the carboxylic acid group replaced with carboxomide).
-
K⁴ – L-lysine with the amino group at position 6 modified with a side chain; specifically, (AEEA)-(γ-Glu)-(C20 diacid) (where AEEA is 2-[2-(2-aminoethoxy)ethoxy]acetic acid, commonly used as a spacer group in synthetic peptides).
GLP3 / R is synthetically engineered and produced using solid-phase peptide synthesis (SPPS). This is when amino acids are added to a peptide chain and attached to solid resin forming a backbone. After the backbone is synthesized, the molecule is cleaved chemically, then purified. Lipidation modifications also occur, meaning a fatty-acid side chain is added to promote reversible binding to albumin. This modification allows for a longer drug half-life..
HALF-LIFE: WHAT CLINICAL DATA SHOWS
Early pharmacokinetic studies suggest that Retatrutide has a half-life of approximately 6–8 days, placing it in the same range as other long-acting incretin-based peptides.
COMPARISON TO OTHER GLP-1/GIP THERAPIES
→ GLP-1 : Half-life ~7 days
→ GLP-2: Half-life ~5 days
→ GLP-3: Half-life ~6–8 days







GLP3 / Reta


